Alder Biopharmaceuticals Inc (NASDAQ:ALDR) has been assigned a consensus recommendation of “Buy” from the fifteen research firms that are currently covering the firm, Marketbeat.com reports. One equities research analyst has rated the stock with a sell rating, two have issued a hold rating, eleven have given a buy rating and one has given a strong buy rating to the company. The average twelve-month price target among brokers that have updated their coverage on the stock in the last year is $27.55.
A number of research analysts recently issued reports on ALDR shares. Cowen set a $23.00 price target on shares of Alder Biopharmaceuticals and gave the stock a “buy” rating in a research note on Monday, February 26th. Zacks Investment Research upgraded shares of Alder Biopharmaceuticals from a “sell” rating to a “hold” rating in a research note on Thursday, March 1st. Goldman Sachs Group started coverage on shares of Alder Biopharmaceuticals in a research note on Tuesday, April 24th. They issued a “neutral” rating and a $17.00 price target for the company. BidaskClub upgraded shares of Alder Biopharmaceuticals from a “sell” rating to a “hold” rating in a research note on Tuesday, April 3rd. Finally, Mizuho reiterated a “buy” rating and issued a $29.00 price target on shares of Alder Biopharmaceuticals in a research note on Wednesday, March 28th.
In other news, insider Jeffrey T. L. Smith sold 12,161 shares of the business’s stock in a transaction that occurred on Wednesday, May 16th. The shares were sold at an average price of $15.03, for a total transaction of $182,779.83. Following the completion of the sale, the insider now owns 5,871 shares in the company, valued at approximately $88,241.13. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. Also, insider Mark James Litton sold 22,727 shares of the business’s stock in a transaction that occurred on Friday, June 1st. The stock was sold at an average price of $17.84, for a total transaction of $405,449.68. The disclosure for this sale can be found here. Insiders have sold a total of 47,049 shares of company stock valued at $805,303 in the last 90 days. Insiders own 17.40% of the company’s stock.
Several large investors have recently modified their holdings of ALDR. Flinton Capital Management LLC purchased a new stake in shares of Alder Biopharmaceuticals during the 1st quarter worth approximately $100,000. Neuburgh Advisers LLC purchased a new stake in shares of Alder Biopharmaceuticals during the 1st quarter worth approximately $121,000. SG Americas Securities LLC purchased a new stake in shares of Alder Biopharmaceuticals during the 4th quarter worth approximately $132,000. Xact Kapitalforvaltning AB purchased a new stake in shares of Alder Biopharmaceuticals during the 1st quarter worth approximately $142,000. Finally, Shepherd Kaplan Krochuk LLC purchased a new stake in shares of Alder Biopharmaceuticals during the 1st quarter worth approximately $151,000.
Shares of Alder Biopharmaceuticals opened at $18.15 on Monday, Marketbeat.com reports. The company has a quick ratio of 13.30, a current ratio of 13.31 and a debt-to-equity ratio of 0.57. The company has a market capitalization of $1.28 billion, a P/E ratio of -3.67 and a beta of 2.58. Alder Biopharmaceuticals has a fifty-two week low of $8.60 and a fifty-two week high of $20.00.
Alder Biopharmaceuticals (NASDAQ:ALDR) last announced its quarterly earnings data on Tuesday, May 8th. The biopharmaceutical company reported ($1.73) earnings per share for the quarter, missing analysts’ consensus estimates of ($1.23) by ($0.50). research analysts predict that Alder Biopharmaceuticals will post -4.91 EPS for the current year.
Alder Biopharmaceuticals Company Profile
Alder BioPharmaceuticals, Inc operates as a clinical-stage biopharmaceutical company. It discovers, develops, and commercializes therapeutic antibodies to transform the treatment paradigm for patients with migraine and other serious neurological or inflammatory conditions in the United States, Australia, and Ireland.
Receive News & Ratings for Alder Biopharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alder Biopharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.